Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses (2016 - 2026)

Ani Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $16.8 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 22.34% to $16.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.8 million, a 22.34% increase, with the full-year FY2025 number at $16.8 million, up 22.34% from a year prior.
  • Accumulated Expenses hit $16.8 million in Q4 2025 for Ani Pharmaceuticals, up from $14.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ANIP hit a ceiling of $29.8 million in Q3 2024 and a floor of $3.3 million in Q1 2022.
  • Historically, Accumulated Expenses has averaged $11.4 million across 5 years, with a median of $10.1 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: surged 222.13% in 2024 and later plummeted 53.15% in 2025.
  • Tracing ANIP's Accumulated Expenses over 5 years: stood at $7.6 million in 2021, then surged by 34.8% to $10.3 million in 2022, then plummeted by 45.64% to $5.6 million in 2023, then soared by 145.01% to $13.7 million in 2024, then rose by 22.34% to $16.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for ANIP at $16.8 million in Q4 2025, $14.0 million in Q3 2025, and $14.8 million in Q2 2025.